GSK PLC closed 20.35% short of its 52-week high of £18.24, which the company achieved on May 16th.
UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...
GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...
The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...
GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
普祺医药产品管线涵盖皮肤、眼科、呼吸、膜性肾病等未被满足临床需求的疾病领域。目前，公司核心产品PG-011（Pumecitirib，普美昔替尼）凝胶已完成治疗针对成人轻中度特应性皮炎的 llb 期临床试验并进入 lll 期临床试验阶段， lIb ...
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
今日，市值748.8亿美元、毛利率高达71.81%的制药巨头GSK plc（LSE/NYSE: GSK）宣布完成对波士顿生物制药公司IDRx, Inc.的收购。此项交易总额可达11.5亿美元，包括10亿美元的首付款和潜在的里程碑付款。根据 InvestingPro 数据显示，GSK保持着强劲的财务健康状况，为战略收购奠定了良好基础。
市值740亿美元的全球制药巨头GSK plc（LSE/NYSE: GSK）今日宣布，将任命牛津大学医学科学部主任Gavin Screaton博士为公司独立非执行董事，任期自2025年5月1日起生效。Screaton博士将接替服务九年后退休的Jesse ...
GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback